Get the latest news, insights, and market updates on LQDA (Liquidia Corporation). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
A Fresh Look at Liquidia (LQDA) Valuation Following Recent Share Price Surge
Liquidia (LQDA) has seen its stock price move recently, prompting some investors to take a fresh look at the company’s performance over the past month. Shares have climbed 30%, raising questions about what is behind the momentum. See our latest analysis for Liquidia. While Liquidia’s latest 30% surge in share price over the past month has drawn attention, it caps off a period of strong momentum. The stock is now up 140.58% year-to-date and boasts a 1-year total shareholder return of 173.33%... Nov 22, 2025 - $LQDA
United Therapeutics Stock, Up 72% Since August, Nears Buy Point Of Rare Base
After consolidating for several months at the end of 2024, United Therapeutics stock made a comeback in early September this year. United Therapeutics stock is now trading above all its key moving averages, and has managed to form a rare ascending base that can elicit big stock gains. Most impressively, the stock's relative strength line has trended sharply higher in recent weeks, showing real power. Nov 21, 2025 - $LQDA
Raymond James Remains Bullish on Liquidia (LQDA), Cites YUTREPIA’s 75% Growth in U.S. Prostacyclin Revenue
With significant upside potential, Liquidia Corporation (NASDAQ:LQDA) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts. On November 4, 2025, Raymond James raised its price target on Liquidia Corporation (NASDAQ:LQDA) from $41 to $47, while reiterating a “Strong Buy” rating. The investment firm’s bullish stance reflects YUTREPIA’s […] Nov 17, 2025 - $LQDA
Is Liquidia's Valuation Justified After 130% Surge on Drug Approval and Patent News?
If you have ever wondered whether Liquidia is a bargain or overpriced, you are not alone. The answer is more interesting than you might expect. Liquidia’s stock price has increased by 20.6% in just the past week and is up an impressive 130.7% year-to-date, showing serious momentum and catching the attention of growth-minded investors. The surge in price has been fueled by recent announcements about new drug approvals and ongoing patent litigation, both of which have significant implications... Nov 5, 2025 - $LQDA
Liquidia (LQDA) Climbs 10.7%, Nears 52-Week High on Strong Demand for Heart Treatment
We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Liquidia Corp. (NASDAQ:LQDA) is one of the best-performing stocks on Tuesday. Liquidia soared by 10.67 percent on Tuesday to close at $27.91 apiece, just 92 cents shy of its highest 52-week price, as investor sentiment was bolstered by strong demand for its pulmonary hypertension treatment. […] Nov 5, 2025 - $LQDA
Liquidia (LQDA): Losses Have Grown 25.7% Annually, High Growth Forecasts Set Tone for Earnings
Liquidia (LQDA) remains unprofitable, with losses having increased at a rate of 25.7% per year over the past five years. Looking ahead, earnings are forecast to grow at 62.69% per year and revenue is projected to increase by 43.7% annually, which is well ahead of the US market average. The combination of above-average growth expectations and a potential path to profitability in the next three years puts a spotlight on how investors are weighing the long-term opportunity versus historical... Nov 4, 2025 - $LQDA
Assessing Liquidia (LQDA) Valuation After Recent Momentum and Strong Shareholder Returns
Liquidia (LQDA) has been gaining attention in recent weeks, with the stock jumping 3% over the past day and a robust 25% over the past 3 months. Investors are keeping an eye on its momentum. See our latest analysis for Liquidia. Liquidia’s recent run stands out as more than just a short-term blip. After an impressive 108% year-to-date share price return and a remarkable 141% total shareholder return over the past year, momentum has certainly been building, especially as ongoing industry buzz... Nov 4, 2025 - $LQDA
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascula Nov 3, 2025 - $LQDA
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today that members of the company’s executive leadership team will be providing updates on the company's business during fireside chats at the following two investor conferences in November: 2025 UBS Global Healthcare Conference on Monday, November 10 beginning at 4:15 p.m. ET in Palm Nov 3, 2025 - $LQDA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple